In adults with non-promyelocytic @entity3052 ( @entity3052 ), high-dose @entity2592 consolidation therapy has been shown to influence survival in selected @entity1 , although the appropriate doses and schemes have not been defined. We evaluated survival after calculating the actual dose of @entity2592 that @entity1 received for consolidation therapy and divided them into 3 groups according to dose. We conducted a single-center, retrospective study involving 311 non-promyelocytic @entity3052 @entity1 with a median age of 36 years (16-79 years) who received curative treatment between 1978 and 2007. The 131 @entity1 who received @entity2592 consolidation were assigned to study groups by their @entity2592 dose protocol. Group 1 (n=69) received <1.5 g/m2 every 12 h on 3 alternate days for up to 4 cycles. The remaining @entity1 received high-dose @entity2592 (>= 1.5 g/m2 every 12 h on 3 alternate days for up to 4 cycles). The actual dose received during the entire consolidation period in these @entity1 was calculated, allowing us to divide these @entity1 into 2 additional groups. Group 2 (n=27) received an intermediate-high-dose (<27 g/m2), and group 3 (n=35) received a very-high-dose (>= 27 g/m2). Among the 311 @entity1 receiving curative treatment, the 5-year survival rate was 20.2% (63 @entity1 ). The @entity2592 consolidation dose was an independent determinant of survival in multivariate analysis; age, karyotype, induction protocol, French-American-British classification, and de novo @entity1778 were not. Comparisons showed that the risk of @entity204 was higher in the intermediate-high-dose group 2 (hazard ratio [HR]=4.51; 95% confidence interval [CI]: 1.81-11.21) and the low-dose group 1 (HR=4.43; 95% CI: 1.97-9.96) than in the very-high-dose group 3, with no significant difference between those two groups. Our findings indicated that very-high-dose @entity2592 during consolidation in adults with non-promyelocytic @entity3052 may improve survival.

Possible benefit of consolidation therapy with high-dose @entity2592 on overall survival of adults with non-promyelocytic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
